Table 3.

Biomarkers significantly correlated^* with structural damage endpoints at Weeks 28 and 52.

Biomarker Timepoint	Biomarker	Efficacy Measure	Placebo + MTX			Combined Golimumab ± MTX
Biomarker Timepoint	Biomarker	Efficacy Measure	N	R	p	N	R	p
		Change at Week 28 in:
Baseline	α-2 macroglobulin	Erosion score	23	0.480	0.021	71	−0.057	0.635
	BAP	JSN score	36	0.447	0.006	109	−0.016	0.870
	Haptoglobin	JSN score	23	0.486	0.019	70	−0.014	0.907
	IL-1ra	Erosion score	23	−0.311	0.149	69	0.246	0.042
	VEGF^**	Erosion score	34	0.522	0.002	105	−0.017	0.863
Change at Week 4	CD40L	Total vdH-S score	23	0.532	0.009	71	−0.007	0.956
	EGF	Erosion score	23	0.479	0.021	70	−0.045	0.714
	EGF	Total vdH-S score	23	0.492	0.017	70	−0.154	0.203
	MMP-3^**	Total vdH-S score	36	0.374	0.025	111	−0.062	0.517
		Change at Week 52 in:
Baseline	COL 2–3/4C LN	Total vdH-S score	35	−0.448	0.007	103	−0.051	0.607
	Deoxypyridinoline	Erosion score	33	−0.483	0.004	102	−0.063	0.532
	Deoxypyridinoline	Total vdH-S score	33	−0.354	0.043	102	0.054	0.592
	IL-1ra	Erosion score	21	−0.449	0.041	64	0.197	0.118
	IL-1ra	Total vdH-S score	21	−0.452	0.040	64	0.247	0.049
Change at Week 4	CD40L	Erosion score	21	0.606	0.004	66	0.083	0.507
	CD40L	JSN score	21	0.541	0.011	66	−0.143	0.252
	CD40L	Total vdH-S score	21	0.656	0.001	66	0.030	0.810
	COL 2–3/4C LN	JSN score	35	−0.433	0.009	103	0.097	0.328
	COL 2–3/4C LN	Total vdH-S score	35	−0.367	0.030	103	0.107	0.282
	EGF	Erosion score	21	0.460	0.036	65	−0.119	0.344
	EGF	JSN score	21	0.417	0.060	65	−0.272	0.029
	EGF	Total vdH-S score	21	0.471	0.031	65	−0.224	0.072
	MIP1ß	Total vdH-S score	21	0.470	0.032	65	−0.045	0.721
	MMP-3^**	JSN score	21	0.460	0.036	66	−0.050	0.688

↵* Defined as p < 0.05 and R ≥ 0.3 for either placebo + MTX or combined golimumab.
↵** Individual serum assays. BAP: bone alkaline phosphatase; CD40L: CD40 ligand; COL 2–3/4C LN: type 2 collagenase long neoepitope; EGF: epidermal growth factor; IL-1ra: interleukin 1 receptor antagonist; JSN: joint space narrowing; MIP1ß: macrophage inflammatory protein 1ß; MMP-3: matrix metalloproteinase-3; MTX: methotrexate; vdH-S: van der Heijde-Sharp score; VEGF: vascular endothelial growth factor.